Trial Profile

Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MNPR-101-Zr (Primary)
Indications Colorectal cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Focus First in man; Pharmacokinetics
Sponsors Monopar Therapeutics

Most Recent Events

22 May 2025 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
22 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Apr 2026.
22 Oct 2024 According to a Monopar Therapeutics media release, company is presenting today , MNPR-101-Zr clinical development program details at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com